A Study to Evaluate BioMarkers in Blood Samples in Subjects with Rheumatoid Arthritis

Study identifier:CD-IA-INDP-1056

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Study to Evaluate Biomarkers in Blood and Synovial Fluid in Subjects with Rheumatoid Arthritis

Medical condition

Arthritis

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

Study type

Observational

Age

18 Years - 75 Years

Date

Study Start Date: 01 Mar 2011

Primary Completion Date: 01 Nov 2012

Study Completion Date: 01 Mar 2013

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Not applicable
Masking: Not applicable
Primary Purpose: -

Verification:

Verified 01 Jul 2013 by MedImmune, LLC

Collaborators

AstraZeneca

Inclusion and exclusion criteria

Inclusion Criteria

- Age 18 through 75 years at time of screening.
- Written informed consent and any locally required authorization (eg, HIPAA in the USA), obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
- A diagnosis of: a) Adult onset RA as defined by the 1987 ACR classification criteria (see Appendix 1), with at least 4 tender and 4 swollen joints at screening (Day 1). Tender/swollen joints must be a part of the 28-joint count included in the Disease Assessment Score 28 (DAS28) assessment; b) Osteoarthritis (OA) of the knee or acute pseudogout attack of the knee.
- Age ≥ 16 years at the time of onset of RA or onset of OA, pseudogout.
- Subjects should either not receive oral corticosteroids, or if receiving oral
corticosteroids, need to be on a stable dose of oral prednisone (or equivalent) ≤ 10 mg/day for at least 4 weeks prior to screening (Day 1).
- Ability and willingness to complete the study until Day 120 as required by the
protocol.

Exclusion Criteria

- History or current inflammatory joint disease other than RA, OA, or pseudogout (eg, gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other autoimmune disorder (systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, or overlap syndrome).
- Any neurological (congenital or acquired), psychiatric, vascular, or systemic disorder could also affect the evaluation of disease assessments; in particular, joint pain and swelling.
- Treatment with IFN-α or IFN-β.
- Intra-articular, IM, or IV corticosteroid injections within 28 days before screening (Day 1).
- Known history of or positive test result for human immunodeficiency virus (HIV).
- Serious infection (eg, pneumonia, septicemia) within the 2 months prior to Day 1 visit.
- Active bacterial or viral infection (which includes ongoing and/or chronic infections such as hepatitis, tuberculosis, etc).
- Concomitant use of systemic antiviral, antibiotic, or antifungals for the treatment of active infection within 28 days of Day 1.
- History of malignancy or evidence of active or suspected malignancy (with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix > 1 year before randomization into the study).
- Vaccinations within 4 weeks of Day 1 visit.
- Concurrent enrollment in another clinical study.
- Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
- Other unspecified reasons that, in the opinion of the Investigator or medical monitor, make the subject unsuitable for participation or confound the data.

No locations available

Arms	Assigned Interventions
Rheumatoid Arthritis Subject must have RA with inflamed joint	Other: Blood samples Subjects will have visits on Days 1, 30 and 120. Other: Synovial fluid aspiration Subjects will have visits on Days 1, 30, and 120. Other: Synovial tissue sample Subjects will have visits on Days 1, 30, and 120.
Osteoarthritis Subjects must have OA of the knee	Other: Blood samples Subjects will have visits on Days 1, 30 and 120. Other: Synovial fluid aspiration Subjects will have visits on Days 1, 30, and 120. Other: Synovial tissue sample Subjects will have visits on Days 1, 30, and 120.
Pseudo gout Subjects must have peusdo-gout of knee	-

Documents available

Click here and search for drug information provided by the FDA.
Download
Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
Download
Click here to find results for studies related to marketed products.
Download
Trial Results Summaries
Available here

Contacts

Contact

Christopher DaCosta

301-398-0000

[email protected]

Investigators

Principal Investigator

Warren Greth

MedImmune